Cowpea (*Vigna unguiculata*) is the protein backbone of West Africa — *akara*, *moin-moin*, *gbegiri*, *waakye*, *kosai*. Nigeria grows about 45% of the world's cowpea, roughly 2.6 million tonnes a year on 4 million hectares, mostly in the Sudan and Sahel zones. It is also the crop most ravaged by *Maruca vitrata*, the pod-borer moth, which in untreated fields routinely destroys 60–90% of the harvest. The smallholder response is repeated sprays of organophosphate insecticides — often unlabelled, often applied without protective equipment, often inside the seven-day pre-harvest window. Pod-borer is, in a real sense, a poisoning problem disguised as a yield problem.
## The breeding programme
From 2009, the Institute for Agricultural Research (IAR), Ahmadu Bello University, Zaria — led by Professor Mohammad Faguji Ishiyaku — ran the Nigerian arm of an international Bt-cowpea programme alongside CSIRO Australia, Donald Danforth Center, USAID and AATF. The technology was a single *Cry1Ab* transgene from *Bacillus thuringiensis*, introgressed by backcrossing into the popular Nigerian variety SAMPEA-7. The result was named SAMPEA 20-T (Tela cowpea, where Tela = 'transgenic').
IAR ran four years of confined field trials (2009–13), then multi-location open field trials in three agroecological zones. Yields in unsprayed plots rose from ~350 kg/ha to ~1,250 kg/ha. Insecticide sprays fell from a typical 6–8 per season to 2 — only for non-Maruca pests.
## The regulatory milestone
On 22 January 2019, the National Biosafety Management Agency (NBMA) issued the Commercial Release Permit for SAMPEA 20-T. On 5 December 2019 the National Variety Release Committee gazetted it. It became the first transgenic food crop ever commercially released anywhere in the world for cowpea — a crop almost no one outside West Africa grows, which is why no Monsanto or Bayer ever attempted it.
The institutional point matters: the technology was integrated, the trials were run, and the dossier was assembled at a Nigerian federal university institute. SAMPEA 20-T is registered in the Nigerian National Variety Catalogue. Ghana issued its own permit for the same line in 2022. Burkina Faso is in trials.
## What it changed
By the 2023 cropping season, IAR estimated roughly 200,000 farmers had planted Tela cowpea. AATF surveys reported median income gains of 20–40% per cropping cycle for adopters versus non-adopters, primarily from the collapse in pesticide spend rather than the yield gain alone. Hospital admissions for organophosphate poisoning in surveyed Kaduna and Kebbi LGAs fell measurably during the 2021 and 2022 spray windows.
## What it has not yet changed
Seed multiplication remains the bottleneck. Tela seed is sold through licensed seed companies (Premier Seeds, Maina Seeds, Da-AllGreen) under a royalty-free arrangement coordinated by AATF, but volumes still fall short of demand. Some farmers re-use saved seed; the technology is largely robust to second-generation use because the trait is dominant, but stewardship — refuge planting to prevent Maruca resistance evolution — is uneven.
The second-generation PBR cowpea stack (Cry1Ab + Cry2Ab to delay resistance) is in confined trial at IAR as of 2024.
## Why this is a Niprisan-rule breakthrough
The lead inventor is Nigerian. The institution of record is Nigerian. The trials, the gazette, the registry are Nigerian. The international collaborators provided the construct; the integration, validation, and release work was IAR's. This is the rare case where Nigerian biotech reached commercial release first — not after the rest of the world.
It sits in the same family as Niprisan (a Nigerian-laboratory product reaching market under a Nigerian regulator) — but with one difference. Tela has not (yet) collapsed. The next five years will tell whether it is the exception that stayed, or the next exhibit in the catalogue of breakthroughs that stalled at scale.